PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL – QNT Press Release


  • F-18 Pivalate PET shows high uptake regardless of origin of primary tumor
  • F-18 Pivalate can be used to monitor cerebral metastases
  • Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake

MELBOURNE, Australia, Oct. 18, 2022 /PRNewswire/ — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London’s F- 18 Pivalate (RAD 101) has achieved successful Phase 2a data in patients with brain metastases, having shown significant tumour uptake that was consistent and independent from the tumour origin.

A full presentation…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center